Russ Conroy is an Assistant Editor for CancerNetwork. He grew up in Hillsborough, New Jersey, and graduated from Rutgers University-New Brunswick in 2022.
On the weekends, he likes to unwind by playing video games with friends, tailgating at Rutgers football games with his family, or building his music collection with a visit to Princeton Record Exchange.
FDA Accepts sBLAs for Enfortumab Vedotin/Pembrolizumab in Advanced or Metastatic Urothelial CancerDecember 21st 2022
The FDA has set the Prescription Drug User Fee Act date for April 21, 2023 for each supplemental biologics license application of enfortumab vedotin-ejfv and pembrolizumab in urothelial carcinoma.
FDA Approves Additional Indication for Pemetrexed Injection Plus Pembrolizumab/Chemo in Metastatic NSCLCDecember 19th 2022
The FDA has approved an additional indication for pemetrexed injection plus pembrolizumab and chemotherapy in the treatment of metastatic non–small cell lung cancer without EGFR or ALK tumor aberrations.
Cabozantinib/Atezolizumab Fails to Reach Survival End Point But Is Safe in Metastatic NSCLCDecember 16th 2022
Findings from the phase 3 CONTACT-01 trial indicated that cabozantinib and atezolizumab did not reach the primary end point of overall survival in patients with metastatic non–small cell lung cancer.
Teclistamab Combination Therapy Produces Promising Safety Profile in Relapsed/Refractory Multiple MyelomaDecember 10th 2022
Findings from the phase 1b MajesTEC-2 trial indicated that teclistamab in combination with daratumumab and lenalidomide demonstrated potential for deep and durable responses in relapsed or refractory multiple myeloma.
FDA Grants Breakthrough Therapy Designation to Revumenib for Relapsed/Refractory KMT2Ar Acute LeukemiaDecember 6th 2022
Revumenib, which was given a breakthrough therapy designation by the FDA, may be beneficial in the management of relapsed or refractory KMT2A-rearranged acute leukemia based on data from the phase 1 AUGMENT-101 trial.
Dostarlimab/Chemotherapy Combo Elicits Significant Survival Benefit in Advanced/Recurrent Endometrial CancerDecember 6th 2022
Treatment with dostarlimab plus chemotherapy demonstrated a statistically significant improvement in progression-free survival compared with placebo and chemotherapy among patients with advanced or recurrent endometrial cancer.
Adjuvant Pembrolizumab Improves Quality-of-Life Vs Interferon α or Ipilimumab in Resected MelanomaDecember 5th 2022
A secondary analysis from the phase 3 SWOG S1404 trial indicated that adjuvant pembrolizumab yielded improved patient-reported outcomes compared with high-dose interferon α or ipilimumab in the treatment of patients with high-risk resected melanoma.
FDA Accepts BLA for Denileukin Diftitox in Cutaneous Persistent/Recurrent T-Cell LymphomaDecember 4th 2022
The FDA’s acceptance of the biologics license application for denileukin diftitox for the treatment of patients with cutaneous persistent or recurrent T-cell lymphoma was supported by data from a pivotal phase 3 trial.
FDA Grants Fast Track Designation to Batiraxcept for Kidney Cancer SubsetNovember 30th 2022
The FDA’s decision to grant fast track designation to batiraxcept for treating patients with advanced or metastatic clear cell renal cell carcinoma — a type of kidney cancer — was supported by data from a phase 1b trial.
Daratumumab Combination Demonstrates Efficacy in Relapsed/Refractory Myeloma With EMDNovember 30th 2022
Among patients with extramedullary multiple myeloma, a regimen consisting of daratumumab plus dexamethasone, cyclophosphamide, etoposide, and cisplatin yielded a complete remission rate of 35.5% and an overall response rate of 67.7%.
Addition of Rezvilutamide to ADT Improves OS and rPFS Vs Bicalutamide/ADT in Hormone-Sensitive Prostate CancerNovember 30th 2022
Rezvilutamide with androgen-deprivation therapy yielded improved overall survival and radiographic progression-free survival compared with bicalutamide and androgen-deprivation therapy in patients with high-volume metastatic hormone-sensitive prostate cancer.
Real-World Findings Suggest mFOLFOX6 Treatment Resulted in Less Oxaliplatin Vs Historic Control in Colon CancerNovember 29th 2022
Real-world patients with stage III colon cancer who were treated in the community practice setting with modified FOLFOX6 received less oxaliplatin vs historic controls from the phase 3 MOSAIC trial.
Data Support Whole Brain Irradiation Reduction in Pediatric Cancer SurvivorsNovember 28th 2022
Results from a pooled case control study indicate that meninges are very radiosensitive in pediatric patients who were treated at prior to age 10 years, supporting reduced dose whole brain irradiation in this population.
Cilta-cel Produces Early Long-Lasting Responses in Pretreated Relapsed/Refractory Multiple MyelomaNovember 28th 2022
Data from the phase 2 CARTIFAN-1 study highlighted a favorable risk-benefit profile for a single infusion of ciltacabtagene autoleucel among patients with relapsed/refractory multiple myeloma.
Neeraj Agarwal, MD, Discusses Potential Link Between ctDNA, AR Aberrations, and Survival in mCSPCNovember 26th 2022
The appearance of circulating tumor DNA and androgen receptor aberrations yielded lower overall survival rates for patients with metastatic castration-sensitive prostate cancer during the phase 3 TITAN trial, according to Agarwal, MD.
Sara Hurvitz, MD, Discusses The HER2-Low Breast Cancer Landscape Following 2022 ASCO, Cites Need for Future InvestigationNovember 25th 2022
According to Hurvitz, the findings of trials such as DESTINY-Breast04 and TROPiCS-02 shed light on potential new therapies for breast cancer, though more research is needed to address new agents and other unmet needs.
Antonio Calles, MD, Highlights Promising Preliminary Activity of Lurbinectedin and Pembrolizumab in Relapsed SCLCNovember 25th 2022
Early results from the phase 1/2 LUPER study indicated that lurbinectedin in combination with pembrolizumab demonstrated no unexpected toxicities and promising preliminary efficacy in the second line for patients with relapsed small cell lung cancer, according to Antonio Calles, MD.
‘Virtually All Patients’ with Newly Diagnosed Transplant-Ineligible Myeloma Achieve Response With Addition of Daratumumab to Lenalidomide-Dexamethasone ComboNovember 24th 2022
According to an expert, more than 90% of patients with newly diagnosed transplant-ineligible multiple myeloma treated with daratumumab plus lenalidomide and dexamethasone will achieve some type of response.
Melanie Wain Kier, MD, MBA Discusses Socioeconomic Disparities in Supportive Therapies for HR+ Breast CancerNovember 24th 2022
Income- and race-related disparities concerning supportive therapies for hormone receptor–positive breast cancer require further study to ensure equitable care and access for all patients, according to Melanie Wain Kier, MD, MBA.
European Commission Approves Cemiplimab for Recurrent/Metastatic Cervical CancerNovember 23rd 2022
The European Commission’s approval of cemiplimab for recurrent or metastatic cervical cancer marks the first second-line immunotherapy option available for this patient population regardless of tumor histology.
Pembrolizumab/Chemotherapy Meets Survival End Point in HER2– Advanced/Metastatic Gastric/GEJ AdenocarcinomaNovember 22nd 2022
Pembrolizumab plus chemotherapy yielded a significant improvement in overall survival compared with placebo plus chemotherapy in patients with HER2-negative advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
Mobocertinib Receives Positive NICE Opinion for Previously Treated EGFR Exon 20 Insertion–Mutated NSCLCNovember 22nd 2022
The National Institute for Health and Care Excellence has given a positive opinion of mobocertinib as a treatment for previously treated advanced non-small cell lung cancer with EGFR exon 20 insertion mutations.
Zandelisib Demonstrates Promising Responses in Relapsed/Refractory Non-Hodgkin LymphomaNovember 21st 2022
Topline results from the phase 2 MIRAGE study indicated that patients with relapsed/refractory indolent B-cell non-Hodgkin lymphoma receiving zandelisib experienced an objective response rate of 75.4%.
Adjuvant Capecitabine Plus Concurrent CRT Yields FFS Benefit in Locoregionally Advanced LA-NPCNovember 20th 2022
Adjuvant capecitabine following concurrent chemoradiotherapy yielded higher failure-free survival rates compared with chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma.